Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Appili Therapeutics Inc T.APLI

Alternate Symbol(s):  APLIF

Healthcare
Appili Therapeutics Inc. is a Canada-based biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. The Company is advancing a diverse range of anti-infectives, including ready-made suspension of metronidazole for the treatment of antimicrobial infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Its anti-infective product development portfolio includes three programs: LIKMEZ (ATI-1501), ATI-1701 and ATI-1801. LIKMEZ (ATI-1501) is its advanced commercial stage asset, a liquid oral reformulation of the antibiotic metronidazole to treat serious anaerobic and protozoal infections. ATI-1701 is a live-attenuated vaccine for Francisella tularensis (F. tularensis), the bacterium which causes tularemia. ATI-1801 is a topical formulation of paromomycin (15% w/w) under advanced clinical development for the treatment of cutaneous leishmaniasis.


TSX:APLI - Post by User

Appili Therapeutics Inc > Market is clearly "random"...
Bullboard Posts
Next >>
User Avatar Image
(800)
•••
Post by SouthernTierTomon Aug 24, 2020 2:00pm
234 Views
Post# 31446597

Market is clearly "random"...

Market is clearly "random"...
Recent Trades - Last 10 of 119
Time ET Ex Price Change Volume Buyer Seller Markers
13:42:55 V 0.85 -0.08 500 1 Anonymous 1 Anonymous K
13:41:37 V 0.85 -0.08 500 1 Anonymous 1 Anonymous K
13:40:13 V 0.85 -0.08 500 1 Anonymous 1 Anonymous K
13:38:55 V 0.85 -0.08 500 1 Anonymous 1 Anonymous K
13:37:38 V 0.85 -0.08 500 1 Anonymous 1 Anonymous K
13:36:13 V 0.85 -0.08 500 1 Anonymous 1 Anonymous K
13:34:56 V 0.85 -0.08 500 1 Anonymous 1 Anonymous K
13:33:37 V 0.85 -0.08 500 1 Anonymous 1 Anonymous K
13:32:14 V 0.85 -0.08 500 1 Anonymous 1 Anonymous K
13:30:55 V 0.85 -0.08 500 1 Anonymous 1 Anonymous K

Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities